ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
书籍章节

Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis

Pan, Long; Fang, Jing; Tong, Chenhao; Chen, Mingyu; Zhang, Bin; Juengpanich, Sarun; Wang, Yifan*; Cai, Xiujun*浙江大学; 绍兴市人民医院
WORLD JOURNAL OF SURGICAL ONCOLOGY2020-12-31DOI: 10.1186/s12957-019-1767-5
4被引14阅读
引用收藏
分享

摘要

Background Pancreatic adenocarcinoma is a highly lethal malignancy. Neoadjuvant chemo(radio)therapy [NAC(R)T] is recommended to use for borderline resectable pancreatic cancer (BRPC) and high-risk resectable pancreatic cancer (RPC), but no high-level evidence exists. Methods We searched PubMed, EMBASE, Web of Science, and Cochrane library to identify trials comparing survival data of NAC(R)T with SF for RPC or BRPC. Overall survival (OS) was synthesized in analysis of all the patients (intention-to-treat [ITT] analysis) and resected patients respectively. Results The meta-analysis included 17 trials with 2286 participants. For BRPC, NAC(R)T improved OS both in ITT analysis (HR, 0.49; 95% CI, 0.37-0.65; P < 0.001) and in analysis of resected patients (HR, 0.66; 95% CI, 0.51-0.85; P = 0.001) in comparison to SF, accompanied with comparable overall resection rate [odds ratio (OR), 0.69; 95% Cl, 0.41-1.16; P = 0.159]. Disease-free survival, R0 rate, and recurrence were also in favor of NAC(R)T. For RPC, OS in analysis of resected patients was higher with NAC(R)T (HR, 0.75; 95% CI, 0.63-0.89; P = 0.001), but OS in ITT analysis was similar (HR, 1.02; 95% CI, 0.85-1.22; P = 0.818). The overall resection rate (OR, 0.50; 95% Cl, 0.25-0.99; P = 0.048) was lower, but R0 rate was higher with NAC(R)T. No differences in disease-free survival and recurrence between NAC(R)T and SF. Survival benefits of NAC(R)T basically persisted across sensitivity and subgroup analyses. Conclusions This meta-analysis demonstrates that NAC(R)T can provide survival benefits in BRPC patients and a subgroup of RPC patients compared with SF. Future research should focus on investigating the potential biomarkers to screen the subgroup of RPC patients who can benefit from neoadjuvant therapy.

学科与关键词

关键词
Pancreatic adenocarcinomaNeoadjuvant chemo(radio)therapySurgery firstSurvival benefitMeta-analysis
相关
加载中…

文献加载失败,请重试

重试

出版信息

书名
WORLD JOURNAL OF SURGICAL ONCOLOGY
出版社
BMC, CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
出版日期
2020-12-31
资助标注
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81772546]; Key Research and Development Plan Projects of Zhejiang Province [2017C01018]
DOI
10.1186/s12957-019-1767-5
起止页码
1

作者

  • P

    Pan, Long (第一作者)

    zhejiang univ

  • F

    Fang, Jing

    zhejiang univ

查看全部 8 位作者收起作者
  • T

    Tong, Chenhao

    shaoxing peoples hosp

  • C

    Chen, Mingyu

    zhejiang univ

  • Z

    Zhang, Bin

    zhejiang univ

  • J

    Juengpanich, Sarun

    zhejiang univ

  • W

    Wang, Yifan (通讯)

    zhejiang univ

  • C

    Cai, Xiujun (通讯)

    zhejiang univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417